Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Cretostimogene grenadenorepvec by CG Oncology for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Cretostimogene grenadenorepvec is under clinical development by CG Oncology and currently in Phase III for Non Muscle Invasive Bladder Cancer...